 |
|
 |
 |
|
||||||||||||||
Sanofi decided to be Silent till 31st October October 05, 2006 A note has been sent by a research analyst stating that Sanofi is silent to most investors, analysts and the media. It will remain quiet until it announces its quarterly financial results on Oct.31. On October 5th it was reported in Forbes magazine that the silence of Sanofi gave a plenty of reason to be nervous to the Sanofi’s shareholders. It was also included in the article in Forbes magazine that approval for Acomplia Drugs in U.S. has been delayed for seven months. A research analyst Gbola Amusa said “it's clear there's a difference between the ways they communicate, compared to other companies.” A few months ago it was expected that Acomplia will be launched in U.S. market with the different name Zimulti but on the other hand analyst admit that it becomes very hard that FDA will work on Acomplia this year. Forbes says “Neurological side effects seem the most likely reason for the long delay and they could conceivably prevent Acomplia from joining the ranks of blockbuster drugs like Plavix and Lipitor."
|
||||||||||||||
